Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient

Clin Interv Aging. 2020 Apr 23;15:575-581. doi: 10.2147/CIA.S174402. eCollection 2020.


Lower urinary tract symptoms, including urgency, urgency incontinence, frequency, and nocturia, are highly prevalent in older adults and are associated with significant morbidity and impairment in quality of life. When conservative measures such as bladder training fail to improve symptoms, pharmacological management is recommended by national and international guidelines. Mirabegron, an agonist of the β3 adrenergic receptor, demonstrates similar efficacy to the anticholinergic drugs without the risk of anticholinergic effects, but experience and evidence in the very elderly population are limited. This narrative review examines the current evidence base for mirabegron in very elderly adults.

Keywords: ageing; anticholinergic; elderly; mirabegron; overactive bladder; urinary incontinence.

Publication types

  • Review

MeSH terms

  • Acetanilides / adverse effects
  • Acetanilides / therapeutic use*
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Lower Urinary Tract Symptoms / drug therapy
  • Nocturia / drug therapy
  • Patient Safety*
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use*
  • Treatment Outcome
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / prevention & control
  • Urinary Incontinence / drug therapy
  • Urological Agents / adverse effects
  • Urological Agents / therapeutic use*


  • Acetanilides
  • Thiazoles
  • Urological Agents
  • mirabegron